Related Experiment Video

Updated: Jan 2, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Durvalumab for the treatment of non-small cell lung cancer

Shuji Murakami1

  • 1Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.

Expert Review of Anticancer Therapy
|November 30, 2019
PubMed

Insights

Durvalumab shows promise in treating advanced non-small cell lung cancer (NSCLC). This immune checkpoint inhibitor is effective alone or with other drugs, improving survival rates in NSCLC patients.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) has a poor prognosis, with a 5-year survival rate around 15%.
  • Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have transformed NSCLC treatment.
  • Durvalumab, an anti-PD-L1 antibody, is a key agent in this evolving therapeutic landscape.

Purpose of the Study:

  • To review the pharmacological properties, clinical efficacy, and safety of durvalumab.
  • To evaluate durvalumab's role as monotherapy and in combination regimens for NSCLC.
  • To discuss durvalumab's impact on locally advanced and advanced NSCLC management.

Main Methods:

  • Review of Phase I/II studies on durvalumab monotherapy and combination therapy.
  • Analysis of the PACIFIC trial data for durvalumab maintenance therapy post-chemoradiotherapy.
  • Assessment of clinical efficacy, safety, and survival endpoints.

Main Results:

  • Durvalumab demonstrated efficacy and a well-tolerated safety profile in Phase I/II trials for advanced NSCLC.
  • The PACIFIC study met its primary endpoints, showing improved progression-free and overall survival with durvalumab maintenance therapy.
  • FDA approval was granted for durvalumab in unresectable stage III NSCLC following definitive chemoradiotherapy.

Conclusions:

  • Durvalumab represents a significant advancement in NSCLC treatment, particularly as maintenance therapy.
  • Ongoing Phase III trials will further define durvalumab's role in the broader NSCLC therapeutic strategy.
  • Durvalumab offers a new option for patients with advanced NSCLC, improving survival outcomes.
Keywords:
DurvalumabNSCLCPD-1PD-L1immune checkpoint inhibitors

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
396
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
897
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
404